Managing Low-level HIV Viraemia in Antiretroviral Therapy: a Systematic Review and Meta-analysis

Overview

Journal Sex Transm Infect

Specialty Infectious Diseases

Date 2024 Sep 17

PMID 39288983

Authors

Drieda Zace

Lorenzo Vittorio Rindi

Mirko Compagno

Luna Colagrossi

Maria Mercedes Santoro

Massimo Andreoni

Carlo Federico Perno

Loredana Sarmati

Affiliations

Soon will be listed here.

Abstract

Objective: HIV-1 management has advanced significantly with antiretroviral therapy (ART), yet challenges persist, including low-level HIV-1 viraemia (LLV). LLV presents a complex scenario, with varied definitions in the literature, reflecting uncertainties in its clinical interpretation. Questions arise regarding the underlying mechanisms of LLV, whether it signifies ongoing viral replication or stems from other factors. This study aimed to systematically review strategies for LLV management, providing insights into optimal clinical approaches.

Methods: MEDLINE, EMBASE, Cochrane Library, Web of Science and Canadian Agency for Drugs and Technologies in Health were searched for relevant literature on LLV management. We included studies published between 2004 and 2024, assessing interventions such as ART modification, genotypic resistance testing, adherence assessment, performing therapeutic drug monitoring, testing for chronic coinfections and assessing the viral reservoir via HIV DNA quantification. Meta-analyses were conducted where feasible.

Results: The systematic review identified 48 eligible records. Findings indicated limited evidence supporting the effectiveness of ART regimen modification in achieving virological suppression among individuals with LLV. However, studies assessing genotypic resistance testing revealed a significant association between resistance-associated mutations and virological suppression during LLV. Adherence to ART emerged as a critical determinant of treatment efficacy, with interventions showing promise in achieving viral suppression. The clinical utility of therapeutic drug monitoring in managing LLV remained inconclusive. Gaps in the literature were identified regarding follow-up scheduling, managing concurrent chronic infections and assessing inflammatory markers in LLV management.

Conclusions: While ART modification may not consistently achieve virological suppression, genotypic resistance testing may offer insights into treatment outcomes. Adherence to ART emerged as a crucial factor, necessitating tailored interventions. However, further research is needed to elucidate the clinical utility of therapeutic drug monitoring and other management strategies. The study highlights the importance of ongoing research to refine therapeutic approaches and improve patient outcomes in LLV management.

Prospero Registration Number: CRD42024511492.

Citing Articles

Management of low-level HIV viremia during antiretroviral therapy: Delphi consensus statement and appraisal of the evidence.

Rindi L, Zace D, Compagno M, Colagrossi L, Santoro M, Andreoni M Sex Transm Infect. 2024; 100(7):442-449.

PMID: 39288982 PMC: 11503133. DOI: 10.1136/sextrans-2024-056199.

References

Saag M, Gandhi R, Hoy J, Landovitz R, Thompson M, Sax P . Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2020; 324(16):1651-1669. PMC: 11017368. DOI: 10.1001/jama.2020.17025. View

Nettles R, Kieffer T, Simmons R, Cofrancesco Jr J, Moore R, Gallant J . Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis. 2004; 39(7):1030-7. DOI: 10.1086/423388. View

Campillo-Gimenez L, Assoumou L, Valantin M, Pajanirassa P, Villemonteix J, Soulie C . Switch to maraviroc/raltegravir dual therapy leads to an unfavorable immune profile with low-level HIV viremia. AIDS. 2015; 29(7):853-6. DOI: 10.1097/QAD.0000000000000626. View

McMahon D, Jones J, Wiegand A, Gange S, Kearney M, Palmer S . Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis. 2010; 50(6):912-9. PMC: 2897152. DOI: 10.1086/650749. View

Fleming J, Mathews W, Rutstein R, Aberg J, Somboonwit C, Cheever L . Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. AIDS. 2019; 33(13):2005-2012. PMC: 6774874. DOI: 10.1097/QAD.0000000000002306. View

Bouchard A, Bourdeau F, Roger J, Taillefer V, Sheehan N, Schnitzer M . Predictive Factors of Detectable Viral Load in HIV-Infected Patients. AIDS Res Hum Retroviruses. 2021; 38(7):552-560. DOI: 10.1089/AID.2021.0106. View

Zhao M, Zhuo C, Li Q, Liu L . Cytomegalovirus (CMV) infection in HIV/AIDS patients and diagnostic values of CMV-DNA detection across different sample types. Ann Palliat Med. 2020; 9(5):2710-2715. DOI: 10.21037/apm-20-1352. View

Goupil de Bouille J, Collignon M, Capsec J, Guillon L, Le Moal G, Barin F . Low-level HIV viremia is associated with low antiretroviral prescription refill rates and social deprivation. AIDS Care. 2020; 33(11):1445-1450. DOI: 10.1080/09540121.2020.1806198. View

Ryscavage P, Kelly S, Li J, Harrigan P, Taiwo B . Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother. 2014; 58(7):3585-98. PMC: 4068602. DOI: 10.1128/AAC.00076-14. View

10.

Kao S, Liu Z, Wu T, Ku S, Tsai C, Shie S . Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: an observational study in a tertiary hospital in Northern Taiwan, 2017-19. J Antimicrob Chemother. 2020; 76(3):722-728. DOI: 10.1093/jac/dkaa510. View

11.

Swenson L, Min J, Woods C, Cai E, Li J, Montaner J . HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS. 2014; 28(8):1125-34. PMC: 4278403. DOI: 10.1097/QAD.0000000000000203. View

12.

Wu F, Simonetti F . Learning from Persistent Viremia: Mechanisms and Implications for Clinical Care and HIV-1 Cure. Curr HIV/AIDS Rep. 2023; 20(6):428-439. PMC: 10719122. DOI: 10.1007/s11904-023-00674-w. View

13.

Luo D, Wan X, Liu J, Tong T . Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2016; 27(6):1785-1805. DOI: 10.1177/0962280216669183. View

14.

Nzivo M, Waruhiu C, Kangethe J, Budambula N . HIV Virologic Failure among Patients with Persistent Low-Level Viremia in Nairobi, Kenya: It Is Time to Review the >1000 Virologic Failure Threshold. Biomed Res Int. 2023; 2023:8961372. PMC: 10159743. DOI: 10.1155/2023/8961372. View

15.

Gonzalez-Serna A, Swenson L, Watson B, Zhang W, Nohpal A, Auyeung K . A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure. Clin Microbiol Infect. 2016; 22(12):1004.e9-1004.e16. DOI: 10.1016/j.cmi.2016.08.012. View

16.

Bull M, Mitchell C, Soria J, Styrchak S, Williams-Wietzikoski C, Legard J . Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation. AIDS. 2018; 32(11):1389-1401. PMC: 6039404. DOI: 10.1097/QAD.0000000000001824. View

17.

Lo C, Mertz D, Loeb M . Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol. 2014; 14:45. PMC: 4021422. DOI: 10.1186/1471-2288-14-45. View

18.

Wan X, Wang W, Liu J, Tong T . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. PMC: 4383202. DOI: 10.1186/1471-2288-14-135. View

19.

Wirden M, Todesco E, Valantin M, Lambert-Niclot S, Simon A, Calin R . Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice. J Antimicrob Chemother. 2015; 70(8):2347-53. DOI: 10.1093/jac/dkv099. View

20.

Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes D . Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis. 2011; 204(4):515-20. PMC: 3203388. DOI: 10.1093/infdis/jir353. View